Targeted IL-27-based gene therapy in preventing SARS-CoV-2 entry.
Mulia GE., Salameh JE., Figueiredo ML.
Clinical Trial, published in Mol Biol Rep (2026) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Mol Biol Rep (2026)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42435246
- DOI
- 10.1007/s11033-026-12315-7
Abstract (original English)
Background Coronaviruses such as SARS-CoV and SARS-CoV-2 have caused severe respiratory syndromes and prominent global health crises over the past two decades. Despite vaccines and antiviral therapies, treatment limitations persist, particularly in preventing viral entry and addressing emerging variants. ACE2, the primary receptor for SARS-CoV-2, represents a critical target for intervention. Cell-based approaches, including mesenchymal stromal cell therapies, have shown safety and promise in clinical trials. Building on our prior success with IL-27 gene therapy for acute respiratory distress syndrome, we explored ACE2-targeted IL-27 delivery as a potential strategy to reduce SARS-CoV-2 entry. Methods and results We developed an in vitro model using SARS-CoV-2 spike pseudotyped lentivirus to mimic viral entry. Human adipose-derived stromal cells were electroporated with plasmid DNA encoding either ACE2-targeted or non-targeted IL-27, and conditioned media were collected. Two regimens were tested: "prevention," where cells were pre-treated with conditioned media before viral exposure, and "treatment," where conditioned media and pseudotyped virus were added simultaneously. Viral entry was quantified using luciferase reporter activity and genome copy units in HEK293-ACE2 and A549-ACE2 cells. ACE2-targeted IL-27 showed a concentration-dependent trend toward reduced lentiviral entr
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.